"The FDA was kept informed of the survey and product retrieval and after it was essentially complete the FDA requested that we conduct an additional step, which was to conduct a formal recall, and we agreed," Jacobs said. A New York Times report on Friday quoted Committee Chairman Towns, a New York Democrat, as saying the committee was "not getting the kind of information and cooperation from Johnson that I would like." He was cited as saying that J&J had used delaying tactics in its dealings with the committee and in some instances had provided misinformation.

-----

J&J REFUTES CLAIMS On Friday, J&J disputed allegations that the company had executed a "phantom recall." J&J spokeswoman Jacobs said that because there was no safety risk, the company had sought to "remove the affected product from a unique channel -- mainly convenience stores and gas stations -- with as little disruption and consumer confusion as possible." The product was recalled because "McNeil's internal tests showed that some tablets might not dissolve as quickly as intended," she said, adding: "There was no patient health or safety risk, nor any consumer complaints." Jacobs said that wholesalers had been told that the product would be removed from store shelves.

-----

Simply visit each store, locate the product and, if any is found, purchase all of the product." The Motrin recall came to light during a congressional hearing concerning J&J's widespread April recall of its Tylenol, Motrin, Benadryl and Zyrtec products for infants and children. As part of its investigation into the April recall, the U.S. House Committee on Oversight and Government Reform began probing a recall of some adult versions of pain reliever Motrin.

-----

NEW YORK  (Reuters) - Johnson & Johnson planned to remove potentially flawed lots of its Motrin over-the-counter pain reliever from store shelves by having contractors buy stocks of it, documents obtained by Reuters show.One memo under the logo of McNeil Consumer Healthcare, a unit of J&J, instructed a contractor identified as Inmar: "Do not communicate to store personnel any information about this product.

-----

That might compel the committee to take more aggressive action as it looks into drug quality and safety issues raised by the recall, Towns was quoted as saying. Committee spokeswoman Rosenberg confirmed that Towns' remarks in the report were accurate. The report cited Jacobs as saying the company had been very cooperative with the committee and confirmed it had provided about 20,000 pages of documents, made its executives available for interviews and answered queries in a timely manner.
